Table 1.
Participant Characteristics
| Total Cohort | Aβ+ | Aβ− | p-value | |
|---|---|---|---|---|
|
| ||||
| N | 310 | 215 | 95 | |
| Age (years) | 74.8 ± 6.8 | 74.6 ± 6.9 | 75.5 ± 6.6 | 0.60 |
| Sex | 0.65 | |||
| Males | 187 (60.3%) | 132 (61.4%) | 55 (57.9%) | |
| Females | 123 (39.7%) | 83 (38.6%) | 40 (42.1%) | |
| Diagnosis | < 0.001*A | |||
| Cognitively intact (CI) | 92 (29.7%) | 33 (15.3%) | 59 (62.1%) | |
| Mild cognitive impairment (MCI) | 149 (48.1%) | 117 (54.4%) | 32 (33.7%) | |
| Alzheimer’s disease (AD) | 69 (22.2%) | 65 (30.2%) | 4 (4.2%) | |
| Apolipoprotein ε4 (APOE4) allele count | < 0.001*A | |||
| 0 APOE4 alleles | 159 (51.3%) | 74 (34.4%) | 85 (89.5%) | |
| 1 APOE4 alleles | 115 (37.1%) | 105 (48.8%) | 10 (10.5%) | |
| 2 APOE4 alleles | 36 (11.6%) | 36 (16.7%) | 0 (0.0%) | |
| Education (years completed) | 15.7 ± 3.0 | 15.6 ± 3.0 | 15.8 ± 2.8 | 0.88 |
| MMSE score | 26.8 ± 2.6 | 26.1 ± 2.6 | 28.4 ± 1.7 | < 0.001*A |
| CSF VEGF (natural log of pg/mL) | 2.70 ± 0.13 | 2.69 ± 0.13 | 2.74 ± 0.13 | < 0.001*A |
| CSF t-tau (pg/mL) | 98.4 ± 52.1 | 113.8 ± 54.4 | 63.4 ± 20.5 | < 0.001*A |
| CSF p-tau (pg/mL) | 33.9 ± 17.4 | 39.7 ± 17.3 | 20.9 ± 7.6 | < 0.001*A |
Continuous variables shown as mean ± standard deviation. Categorical variables shown as frequency (%). Amyloid group level differences (Aβ- vs. Aβ+) were evaluated on continuous variables using a Welch’s two-sample t-test and categorical variables using a χ2 test.
*
indicates p< 0.05 group difference between Aβ- (n=95) vs. Aβ+ (n=215) participants.
A
indicates p< 0.05 between Aβ- (n=42) vs. Aβ+ (n=116) participants in subset with available FDG-PET data.